Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” first quarter 2021 investor letter –...
Posts Tagged ‘NASDAQ:FOLD’
Is FOLD Stock A Buy or Sell?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first...
Is FOLD A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting...
5 Best Biotech Stocks to Invest In
Below are the 5 best biotech stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman. For a comprehensive review, see...
Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors...
Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings...
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data....
Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted...
2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD)
2018’s fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market...
Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook...
Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)?
Hedge funds are known to underperform the bull markets but that’s not because they are bad at investing. Truth be told, most hedge fund managers...
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse...
Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or...
Hedge Fund and Insider Trading News: Warren Buffett, Elliott Management, Mcdonald’s Corp (MCD), GTT Communications Inc (GTT), Butler National Co. (BUKS), and More
Warren Buffett’s Firm Invests Millions in Fintech (The Wall Street Journal) Warren Buffett’s Berkshire Hathaway Inc. is hopping on the fintech bandwagon...
Hedge Fund and Insider Trading News: Ken Griffin, Carl Icahn, Howard Hughes Corp (HHC), Amicus Therapeutics, Inc. (FOLD), Falcon Minerals Corp (FLMN), and More
Ken Griffin Hires Two Moore Capital Veterans for Macro Expansion (Bloomberg) Billionaire Ken Griffin hired two veteran money managers from Louis Bacon...
Hedge Fund and Insider Trading News: Bill Miller, John Paulson, Warren Buffett, Amicus Therapeutics, Inc. (FOLD), Workday Inc (WDAY), and More
Famed Value Investor Bill Miller Says Facebook Stock has Gotten Too Cheap: ‘This Too will Pass’ (CNBC) Famed investor Bill Miller is still...
Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S. Food and Drug Administration...
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
Amicus Therapeutics, Inc. (NASDAQ:FOLD) says that it will be closing its previously announced private offering of $250 million aggregate principal amount...
Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news. Here...
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors...
Biotech Movers And Shakers: Nivalis Therapeutics Inc (NVLS) And Amicus Therapeutics, Inc. (FOLD)
It’s time to take a look at those stocks that really moved over the last twenty-four hours or so in biotech, and there are plenty to go at. It’s been...
Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two Other Stocks?
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven...
Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS)
While wider markets turn there focus to the US elections, the biotech space is alive and well, and after a tough end to last week, a number of companies...
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
Joseph Edelman‘s Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being...
Five Cheap Healthcare Stocks Poised to Explode
The healthcare sector has witnessed a significant correction in the last 15 months, with many prominent names in the industry losing a noteworthy chunk...
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience...
Amicus Therapeutics, Inc. (FOLD): Small-Cap Biotech with Large Hedge Fund Ownership
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s lead drug candidate is migalastat, which targets Fabry disease. An estimated 1 in 40,000 to 60,000 males...
Why Are Investors Excited About These 5 Stocks Today?
The markets are going nowhere today, after the IMF cut its global growth forecast for the fourth time over the past twelve months, due to China’...
Why Valeant, Micron, and Three Other Stocks Are in Green Territory on Friday?
Oil went back to tumbling on Friday, with crude oil losing more than 3.5%. On the other hand, markets returned to positive territory, with major U.S....
Top Biotech Picks of Best-Performing Hedge Fund of 2015
Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top...
Redmile Group’s Top Q4 Moves as Its Long Positions Show Gains of 20% in 2015
Redmile Group is a San Francisco-based investment firm managed by Jeremy Green, which primarily focuses on the healthcare sector. Redmile has an equity...
Five Cheap Healthcare Stocks Poised to Explode
Over the past few months the healthcare sector has undergone a roller coaster of a ride, especially in August and September when many investors got wary...
The Smart Money Is Hoarding Shares of These 10 Healthcare Stocks: Part 1
Given elite hedge funds have filed their latest 13F’s, we have an opportunity to analyze what hedge funds like and what they don’t like. Since...
Are Hedge Funds Dumping Amicus Therapeutics, Inc. (FOLD)?
The third-quarter stock market correction has turned out to resemble the situation observed during the Asian financial crisis of 1997. The two relatively...
Why Are These Four Stocks Making A Late Surge?
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc. (NASDAQ:NVAX), and Diamond Offshore...
Are The Gains In These Hot Monday Stocks Sustainable?
It’s a good Monday for investors of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Oasis Petroleum Inc. (...
Something that Might Change Your Mind About Two of These Three Falling Stocks
Three stocks trending significantly low today before afternoon were Amicus Therapeutics, Inc. (NASDAQ:FOLD), which cratered by more than 40%, Teladoc...
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX) among Biotech Guru Joseph Edelman’s Top Healthcare Picks
Biotech Guru Joseph Edelman‘s Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks. Edelman founded...
Tuesday Morning Corporation (TUES), Swift Transportation Co (SWFT), Amicus Therapeutics, Inc. (FOLD): Citadel’s Latest Moves
Ken Griffin‘s Citadel Investment Group has increased its stakes in Tuesday Morning Corporation (NASDAQ:TUES), Swift Transportation Co (NYSE:SWFT...
Amicus Therapeutics, Inc. (FOLD): Redmile Group Trims Position and Books Some Profits from Long-Term Investment
Jeremy Green‘s Redmile Group has also reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD), after yesterday, William Leland Edwards’...
Amicus Therapeutics Inc. (FOLD): Palo Alto Investors Sells Half of its Stake At Sky-High Valuation
William Leland Edwards’ Palo Alto Investors disclosed today a 50% decrease in its exposure to Amicus Therapeutics, Inc. (NASDAQ:FOLD). According to...
Perceptive Advisors Buys 4.0 Million Shares Of Amicus Therapeutics Inc. (FOLD)
Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S. Securities and Exchange...
Jeremy Green, Redmile Group Boost Position in Amicus Therapeutics, Inc. (FOLD)
Jeremy Green‘s Redmile Group has significantly surged its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD), a new filing with the SEC revealed...
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
Is BioDelivery Sciences International, Inc. (NASDAQ:BDSI) a good investment? At the moment, there are many indicators market participants can use to...
This Metric Says You Are Smart to Buy Amicus Therapeutics, Inc. (FOLD)
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a good investment? Now, according to many investors, hedge funds are assumed to be overrated, outdated investment...
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
Should Pain Therapeutics, Inc. (NASDAQ:PTIE) investors track the following data? In the eyes of many investors, hedge funds are viewed as overrated,...
Hedge Funds Are Buying ZIOPHARM Oncology Inc. (ZIOP)
Is ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) a buy, sell, or hold? The best stock pickers are taking a bullish view. The number of bullish hedge fund bets...
Hedge Funds Are Buying Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds’ portfolio at the end of March. FOLD shareholders have witnessed an increase in enthusiasm...
Is BioDelivery Sciences International, Inc. (BDSI) Going to Burn These Hedge Funds?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shareholders have witnessed a decrease in hedge fund sentiment of late; stagnant interest is a...
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood. The number of long hedge fund positions were trimmed...
